PHGUF Projected Dividend Yield
Ord (New)/Pharming Group NV ( OTCBB : PHGUF )Pharming Group is a global, commercial stage biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs. Co.'s primary portfolio is its recombinant human C1 esterase inhibitor (rhC1INH) franchise. C1INH is a naturally occurring protein that down-regulates the complement cascade in order to control swelling in affected tissues. Co.'s primary product, RUCONEST® is a plasma-free rhC1INH protein replacement therapy. It is approved for the treatment of acute hereditary angioedema attacks. Co. is also developing rhC1INH for subsequent indications, including pre-eclampsia, and acute kidney injury. 21 YEAR PERFORMANCE RESULTS |
PHGUF Dividend History Detail PHGUF Dividend News PHGUF Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |